Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 3NETWORK 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 16Gastrointestinal 10Tumor-Agnostic 6Thoracic 6Other solid neoplasm 6Gynecologic 4Genitourinary 2Plasma cell 1Other hematologic neoplasm 1Head & Neck 1CNS 1Breast 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 315Bortezomib 166Lenalidomide 132pomalidomide 113daratumumab 96carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × cobimetinib × Plasma cell × Clear all
NCT03312530 2023-02-28

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Hoffmann-La Roche

Phase 1/2 Completed
49 enrolled 24 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡